## STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract:
		Done
		(b) Provide in the abstract an informative and balanced summary of what was done and
		what was found
		Done
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 3
Objectives	3	State specific objectives, including any prespecified hypotheses
		Page 3
Methods		
Study design	4	Present key elements of study design early in the paper
	·	Page 4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
		Pages 4-6
Participants	6	(a) Give the eligibility
1		criteria, and the sources and methods of selection of participants. Describe
		methods of follow-up
		Page 4
		(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
		Pages 4-5
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment
measurement		(measurement). Describe comparability of assessment methods if there is more than
		one group
		Pages 4-5
Bias	9	Describe any efforts to address potential sources of bias
		Stratification by age (page 4), discussion of potential bias in Limitations, page 10
Study size	10	Explain how the study size was arrived at
		Observational study, all available cases included
Quantitative	11	Explain how quantitative variables were handled in the analyses. If applicable, describe
variables		which groupings were chosen and why
		Methods, pages 4-5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) If applicable, explain how loss to follow-up was addressed
		(e) Describe any sensitivity analyses
		Pages 5-6
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially
1 .	-	eligible, examined for eligibility, confirmed eligible, included in the study, completing
		follow-up, and analysed
		1,

		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
		Pages 6-7, Table 1, Flowchart
Descriptive data	14*	(a) Give characteristics
		of study participants (eg demographic, clinical, social) and information on
		exposures and potential confounders
		Table 1, Page 6
		(b) Indicate number of participants with missing data for each variable of interest
		Summarise follow-up time (eg, average and total amount)
		Results page 6, Table 1
Outcome data	15*	Report numbers of outcome events or summary measures over time
		Pages 6-7
Main results	16	(a) Give unadjusted
		estimates and, if applicable, confounder-adjusted estimates and their precision
		(eg, 95% confidence interval). Make clear which confounders were adjusted
		for and why they were included
		Tables 2-3, Figures 3-5
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a
		meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity
		analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
		Discussion, first paragraph (page 8)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
		Limitations, page 10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
		multiplicity of analyses, results from similar studies, and other relevant evidence
		Pages 10-11
Generalisability	21	Discuss the generalisability (external validity) of the study results
		Pages 10-11
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if
		•
		applicable, for the original study on which the present article is based

<sup>\*</sup>Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.